J. Safra Sarasin Holding AG Sells 51,880 Shares of Xenon Pharmaceuticals Inc. $XENE

J. Safra Sarasin Holding AG trimmed its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 63.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,168 shares of the biopharmaceutical company’s stock after selling 51,880 shares during the period. J. Safra Sarasin Holding AG’s holdings in Xenon Pharmaceuticals were worth $1,211,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in XENE. Farther Finance Advisors LLC acquired a new stake in Xenon Pharmaceuticals in the second quarter valued at approximately $25,000. Elevation Point Wealth Partners LLC bought a new position in shares of Xenon Pharmaceuticals in the 2nd quarter worth $32,000. Osaic Holdings Inc. grew its position in Xenon Pharmaceuticals by 541.4% in the 2nd quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 1,034 shares during the period. L1 Capital Pty Ltd acquired a new stake in Xenon Pharmaceuticals in the 2nd quarter valued at $41,000. Finally, Amalgamated Bank bought a new stake in Xenon Pharmaceuticals during the 2nd quarter valued at $81,000. 95.45% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Xenon Pharmaceuticals

In other news, CEO Ian Mortimer sold 40,000 shares of the firm’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $44.43, for a total transaction of $1,777,200.00. Following the completion of the sale, the chief executive officer directly owned 6,000 shares of the company’s stock, valued at $266,580. This trade represents a 86.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In the last ninety days, insiders sold 65,302 shares of company stock valued at $2,924,128. 4.07% of the stock is owned by corporate insiders.

Xenon Pharmaceuticals Stock Performance

NASDAQ:XENE opened at $41.95 on Thursday. Xenon Pharmaceuticals Inc. has a 52 week low of $26.74 and a 52 week high of $46.60. The firm has a 50-day moving average price of $43.02 and a two-hundred day moving average price of $39.48. The firm has a market cap of $3.24 billion, a price-to-earnings ratio of -10.78 and a beta of 0.97.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Monday, November 3rd. The biopharmaceutical company reported ($1.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.01. Xenon Pharmaceuticals’s quarterly revenue was up .0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.81) earnings per share. As a group, sell-side analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on XENE. Needham & Company LLC reiterated a “buy” rating and set a $55.00 price objective on shares of Xenon Pharmaceuticals in a report on Tuesday, November 4th. Wells Fargo & Company raised their price target on shares of Xenon Pharmaceuticals from $44.00 to $48.00 and gave the company an “overweight” rating in a research report on Thursday, December 11th. Bloom Burton raised Xenon Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, October 7th. Chardan Capital raised Xenon Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, November 19th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday, November 4th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $54.82.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.